Do Cytokeratin-Positive-Only Sentinel Lymph Nodes Warrant Complete Axillary Lymph Node Dissection in Patients with Invasive Breast Cancer?
- 1 June 2000
- journal article
- Published by SAGE Publications in The American Surgeon
- Vol. 66 (6) , 574-578
- https://doi.org/10.1177/000313480006600609
Abstract
The small number of nodes harvested with lymphatic mapping and sentinel lymph node (SLN) biopsy has allowed a more detailed pathologic examination of those nodes. Immunohistochemical stains for cytokeratin (CK-IHC) have been used in an attempt to minimize the false negative rate for SLN mapping. This study examines the value of CK-IHC positivity in predicting further lymph node involvement in the axillary basin. From April 1998 through May 1999, 519 lymphatic mappings and SLN biopsies were performed for invasive breast cancer. SLNs were examined by imprint cytology, hematoxylin and eosin (H&E), and CK-IHC. Patients with evidence of metastatic disease by any of the above techniques were eligible for complete axillary node dissection (CAND). The frequency with which these modalities predicted further lymph node involvement in the axillary basin was compared. Of the 519 lymphatic mappings, 39 patients (7.5%) had a CK-IHC-positive-only SLN. Five (12.8%) of these 39 patients had at least 2 SLNs positive by CK-IHC. Twenty-six of the CK-IHC-positive-only patients underwent CAND. Three of these 26 patients (11.5%) had additional metastases identified after CAND. The sensitivity levels with which each modality detected further axillary lymph node involvement were as follows: CK-IHC, 98 per cent; H&E, 94 per cent; and imprint cytology, 87 per cent. A logistic regression to compare the prognostic value of the three modalities was performed. All were significant, with odds ratios of 19.1 for CK-IHC (P = 0.015), 5.3 for H&E (P = 0.033), and 3.86 for imprint cytology (P = 0.0059). These data validate the enhanced detection of CK-IHC for the evaluation of SLNs. Detection of CK-IHC-positive SLNs appears to warrant CAND in patients with invasive breast cancer. However, the therapeutic value of CAND or adjuvant therapies based on CK-IHC-positive SLNs would be best answered by prospective randomized trials.Keywords
This publication has 18 references indexed in Scilit:
- Therapeutic implications of the sentinel lymph node in breast cancerThe Lancet, 1999
- Techniques for Lymphatic Mapping in Breast CarcinomaSurgical Oncology Clinics of North America, 1999
- Sentinel Node Biopsy and Cytokeratin Staining for the Accurate Staging of 478 Breast Cancer PatientsThe American Surgeon, 1999
- Do All Patients With Sentinel Node Metastasis From Breast Carcinoma Need Complete Axillary Node Dissection?Annals of Surgery, 1999
- Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients With Breast CancerAnnals of Surgery, 1998
- Sentinel Lymphadenectomy: A Safe Answer to Less Axillary Surgery?Published by Springer Nature ,1998
- Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcomeAnnals of Surgical Oncology, 1997
- Improved Axillary Staging of Breast Cancer with Sentinel LymphadenectomyAnnals of Surgery, 1995
- Detection and significance of occult metastases in node-negative breast cancerBritish Journal of Surgery, 1993
- Axillary node dissection for early breast cancer: Some is good, but all is betterJournal of Surgical Oncology, 1992